ÂÜÀòÂÒÂ×

Harlan W. Waksal, M.D., has led several late-stage and commercial biotech and pharmaceutical companies as well as secured successful financial deals after scaling companies during more than 30 years in the industry. He has led teams who have achieved several U.S. Food and Drug Administration (FDA) approvals and blockbuster product launches, including REZUROCKTM (belumosudil), Erbitux (cetuximab), and Cyramaz (ramucirumab). He most recently served as President, Chief Executive Officer and Member of the Board of Directors of Kadmon Holdings prior to its acquisition by Sanofi in November 2021.

Prior to Kadmon, Dr. Waksal served as Member of the Board of Directors and Executive Vice President, Business & Scientific Affairs at Acasti Pharma. Previously, he served as Chairman of the Board of Directors at Senesco Technologies (formerly Sevion Therapeutics). He also co-founded and served as Member of the Board of Directors, Executive Vice President, Chief Operating Officer, and President at ImClone Systems prior to its acquisition by Eli Lilly in 2008.

Dr. Waksal’s additional roles include serving as a Member of the Board of Directors at Neptune Technologies & Bioresources, Observer of the Board of Directors at NeuroBiopharm, Chairman of the American Committee for the Weizmann Institute of Science and Member of the Technology Advisory Board at the New Jersey Edison Innovation Fund. Dr. Waksal holds a B.A. from Oberlin College and an M.D. from Tufts University School of Medicine. He completed his training in internal medicine at New England Medical Center and in pathology at Kings County Hospital Center in Brooklyn.